ImportRefusal LogoImportRefusal

Glaxo Smithkline Consumer Heathcare Ltd

⚠️ Moderate Risk

FEI: 3004181768 • Gurgaon, Haryana • INDIA

FEI

FEI Number

3004181768

📍

Location

Gurgaon, Haryana

🇮🇳

Country

INDIA
🏢

Address

Plaza Tower, , Gurgaon, Haryana, India

Moderate Risk

FDA Import Risk Assessment

34.3
LowModerateHighCritical

This firm has a moderate history of FDA import refusals. Some attention may be warranted.

Statistics

15
Total Refusals
9
Unique Violations
11/9/2015
Latest Refusal
10/17/2006
Earliest Refusal

Score Breakdown

Violation Severity
48.2×40%
Refusal Volume
44.6×30%
Recency
0.0×20%
Frequency
16.5×10%
How is this score calculated?

Proprietary Algorithm

  • 40% Violation Severity — AI-assessed (1-10)
  • 30% Refusal Volume — Logarithmic scale
  • 20% Recency — Decays over 5 years
  • 10% Frequency — Refusals per year

© ImportRefusal.com Original Analysis

Violation Summary

4829×

NUTRIT LBL

The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be misbranded in that the label or labeling fails to bear the required nutrition information.

756×

UNAPPROVED

The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).

3284×

USUAL NAME

The article is subject to refusal of admission pursuant to Section 801(a)(3) of the FD&C Act in that it appears to be misbranded within the meaning of Section 403(i)(1) of the FD&C Act in that the label fails to bear the common or usual name of the food, if any there be.

3244×

NO ENGLISH

The article is subject to refusal of admission pursuant to Section 801(a)(3) of the FD&C Act in that it appears to be misbranded within the meaning of Section 403(f) of the FD&C Act in that any word, statement, or other information required by or under the authority of the FD&C Act to appear on the label or labeling is not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary terms of purchase and use (for example, label contains information in two or more languages but fails to repeat all required information in both languages in accordance with 21 CFR 101.15(c)(2), or label fails to include all required information in English in accordance with 21 CFR 101.15(c)(1), except in the case of articles distributed solely in the Commonwealth of Puerto Rico or in a Territory where the predominant language is one other than English)).

4734×

LABELING

The article appears in violation of FPLA because of its placement, form and/or contents statement.

2183×

LIST INGRE

The article is subject to refusal of admission pursuant to Section 801(a)(3) of the FD&C Act in that it appears to be misbranded within the meaning of Section 403(i)(2) of the FD&C Act in that it is fabricated from two or more ingredients and the label fails to bear the common or usual name of each such ingredient and/or the article purports to be a beverage containing vegetable or fruit juice, but does not bear a statement with appropriate prominence on the information panel of the total percentage of such fruit or vegetable juice contained in the food.

4882×

HEALTH C

The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be misbranded in that the label or labeling bears an unauthorized nutrient content/health claim.

2561×

INCONSPICU

The article is subject to refusal of admission pursuant to Section 801(a)(3) of the FD&C Act in that it appears to be misbranded within the meaning of Section 403(f) of the FD&C Act in that any word, statement, or other information required by or under the authority of the FD&C Act to appear on the label or labeling is not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary terms of purchase and use (for example, label contains information in two or more languages but fails to repeat all required information in both languages in accordance with 21 CFR 101.15(c)(2), or label fails to include all required information in English in accordance with 21 CFR 101.15(c)(1), except in the case of articles distributed solely in the Commonwealth of Puerto Rico or in a Territory where the predominant language is one other than English)).

3211×

LACKS N/C

The article is subject to refusal of admission pursuant to Section 801(a)(3) of the FD&C Act in that it appears to be misbranded within the meaning of Section 403(e)(2) of the FD&C Act in that the food is in package form and the label fails to bear an accurate statement of the quantity of the contents in terms of weight, measure, or numerical count in accordance with Section 403(e)(2) of the FD&C Act.

Refusal History

DateProductViolationsDivision
11/9/2015
30YGT99BEVERAGE BASE NOT MENTIONED ELSEWHERE, N.E.C.
324NO ENGLISH
482NUTRIT LBL
Seattle District Office (SEA-DO)
11/9/2015
30YGT99BEVERAGE BASE NOT MENTIONED ELSEWHERE, N.E.C.
324NO ENGLISH
328USUAL NAME
482NUTRIT LBL
Seattle District Office (SEA-DO)
11/9/2015
30YGT99BEVERAGE BASE NOT MENTIONED ELSEWHERE, N.E.C.
324NO ENGLISH
328USUAL NAME
482NUTRIT LBL
Seattle District Office (SEA-DO)
11/9/2015
30YGT99BEVERAGE BASE NOT MENTIONED ELSEWHERE, N.E.C.
324NO ENGLISH
328USUAL NAME
482NUTRIT LBL
Seattle District Office (SEA-DO)
11/9/2015
30YGT99BEVERAGE BASE NOT MENTIONED ELSEWHERE, N.E.C.
218LIST INGRE
482NUTRIT LBL
488HEALTH C
Seattle District Office (SEA-DO)
9/15/2014
30YGT99BEVERAGE BASE NOT MENTIONED ELSEWHERE, N.E.C.
75UNAPPROVED
Los Angeles District Office (LOS-DO)
9/15/2014
30YGT99BEVERAGE BASE NOT MENTIONED ELSEWHERE, N.E.C.
75UNAPPROVED
Los Angeles District Office (LOS-DO)
9/15/2014
30YGT99BEVERAGE BASE NOT MENTIONED ELSEWHERE, N.E.C.
75UNAPPROVED
Los Angeles District Office (LOS-DO)
9/15/2014
30YGT99BEVERAGE BASE NOT MENTIONED ELSEWHERE, N.E.C.
75UNAPPROVED
Los Angeles District Office (LOS-DO)
9/15/2014
30YGT99BEVERAGE BASE NOT MENTIONED ELSEWHERE, N.E.C.
75UNAPPROVED
Los Angeles District Office (LOS-DO)
9/15/2014
30YGT99BEVERAGE BASE NOT MENTIONED ELSEWHERE, N.E.C.
75UNAPPROVED
Los Angeles District Office (LOS-DO)
3/8/2011
30GGT99BEVERAGE BASE OF NON-FRUIT ORIGIN, LIQUID, N.E.C.
218LIST INGRE
473LABELING
482NUTRIT LBL
Seattle District Office (SEA-DO)
3/8/2011
30GGT99BEVERAGE BASE OF NON-FRUIT ORIGIN, LIQUID, N.E.C.
218LIST INGRE
473LABELING
482NUTRIT LBL
Seattle District Office (SEA-DO)
5/12/2009
09CHT08MILK, MALTED
256INCONSPICU
473LABELING
482NUTRIT LBL
488HEALTH C
Southwest Import District Office (SWI-DO)
10/17/2006
31EFY99COFFEE SUBSTITUTES, N.E.C.
321LACKS N/C
328USUAL NAME
473LABELING
482NUTRIT LBL
Seattle District Office (SEA-DO)

Frequently Asked Questions

What is Glaxo Smithkline Consumer Heathcare Ltd's FDA import refusal history?

Glaxo Smithkline Consumer Heathcare Ltd (FEI: 3004181768) has 15 FDA import refusal record(s) in our database, spanning from 10/17/2006 to 11/9/2015.

What is an FEI number?

FEI stands for Firm Establishment Identifier. It's a unique number assigned by the FDA to identify establishments that manufacture, process, pack, or hold food, drugs, medical devices, or other FDA-regulated products. Glaxo Smithkline Consumer Heathcare Ltd's FEI number is 3004181768.

What types of violations has Glaxo Smithkline Consumer Heathcare Ltd received?

Glaxo Smithkline Consumer Heathcare Ltd has been cited for 9 different violation type(s). Common FDA violations include adulteration (unsafe or unsanitary products), misbranding (incorrect or misleading labels), and regulatory non-compliance.

Where does this information about Glaxo Smithkline Consumer Heathcare Ltd come from?

All FDA import refusal data for Glaxo Smithkline Consumer Heathcare Ltd is sourced from the official FDA Data Dashboard (datadashboard.fda.gov), a public government database maintained by the U.S. Food and Drug Administration.

Data sourced from the FDA Data Dashboard, a public database maintained by the U.S. Food and Drug Administration.